Eminent Gold Acquires New Property in Nevada

1 Mins read

Eminent Gold, a leading gold exploration company, announced on Wednesday its successful acquisition of a new property in Nevada. This property boasts over 100 gold deposit claims and presents an exciting opportunity for the company’s future growth.

The deal involves Eminent Gold exchanging 350,000 of its shares to Orogen Royalties in exchange for the Gilbert South property. Located near Tonopah along the Walker Lane Trend, this property spans an impressive 890 hectares. Furthermore, an additional 200,000 shares will be issued to Orogen Royalties once the drill program commences.

Based on Tuesday’s closing price of Eminent’s stock at 27 Canadian cents per share (20 cents), the total value of the shares being exchanged amounts to approximately C$148,500.

Paul Sun, the Chief Executive of Eminent Gold, expressed his optimism about this acquisition. He believes that the Gilbert South property presents one of the most promising epithermal prospects in the Walker Lane district of Nevada. This acquisition positions the company to explore this renowned historic gold district and further strengthen its foothold in the area.

Eminent Gold’s acquisition of this new property marks a significant milestone for the company. It not only expands their portfolio but also demonstrates their commitment to pursuing strategic opportunities within the gold mining industry.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

23 + = 26